Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis

Eur Respir J. 2019 Sep 30;54(3):1900399. doi: 10.1183/13993003.00399-2019. Print 2019 Sep.

Abstract

New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Double-Blind Method
  • Dyspnea / drug therapy*
  • Dyspnea / physiopathology
  • Female
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy*
  • Male
  • Middle Aged
  • Pyridones / therapeutic use*
  • Quality of Life
  • Severity of Illness Index
  • Sex Factors
  • Surveys and Questionnaires
  • Time Factors
  • Treatment Outcome
  • Vital Capacity

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Pyridones
  • pirfenidone